Investigator to Congress: Ketek data was known to be fraudulent

Share this article:

A subpoenaed FDA criminal investigator has told Congress that Aventis should have known that data it submitted to support the approval of antibiotic Ketek was fraudulent. Agent Douglas Loveland testified that there were so many “red flags” in one study that the company should have notified the FDA. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.